Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C
| Autor: | Spilios, Manolakopoulos, Melanie J, Deutsch, Olga, Anagnostou, Stelios, Karatapanis, Elli, Tiniakou, George V, Papatheodoridis, Ekaterini, Georgiou, Emmanuel, Manesis, Dimitris, Tzourmakliotis, Athanasios J, Archimandritis |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Time Factors Adolescent Genotype Hepacivirus Antiviral Agents Risk Assessment Medication Adherence Drug Users Young Adult Risk Factors Ribavirin Odds Ratio Humans Substance Abuse Intravenous Retrospective Studies Chi-Square Distribution Greece Contraindications Hepatitis C Chronic Middle Aged Viral Load Logistic Models Treatment Outcome RNA Viral Drug Therapy Combination Female Interferons |
| Zdroj: | Liver international : official journal of the International Association for the Study of the Liver. 30(10) |
| ISSN: | 1478-3231 |
| Popis: | International guidelines and routine clinical practice express concerns about antiviral treatment in intravenous drug users (IDUs). We analysed the effect of IDU and/or substitution therapy on chronic hepatitis C (CHC) treatment adherence and response.Intravenous drug users with CHC were divided into three groups: (A) patients on a substitution programme; (B) active users; and (C) past IDUs. Patients were treated according to the standard of care and followed by a specialist team.A total of 175 patients (mean age 39.4±8.8) were included. One hundred and forty-four (65%) were adherent to therapy (completing treatment and 6 months of follow-up). Twenty-two patients (36%) discontinued because of side effects, 28 (46%) discontinued on their own and 11 (18%) completed treatment but did not present at follow-up. Of 142 patients with available treatment outcome, 99 (69.7%) achieved a sustained virological response (SVR), with no differences among the study groups. Patients with genotypes 2-3 and those who completed the treatment schedule had 2.78-fold (95% CI: 1.3-5.8) and 6.4-fold (95% CI: 2.6-15.6) higher probability of achieving SVR.Active use of illicit drugs and/or drug substitution do not affect the treatment outcome in patients with CHC as long as they are closely followed and remain adherent to the treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text